Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.